Table of Contents
Based in the United States, Gilead Sciences is a global leader in the marketing and development of anti-infective drugs. The company has approved products for the treatment of Hepatitis B & C, HIV/AIDS, fungal infections and influenza.
Aruvian Research presents Analysis of Gilead Sciences. A complete and comprehensive analysis of Gilead Sciences, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.
Company analysis from Aruvian includes a history of Gilead Sciences, a business segment analysis of the segments Gilead Sciences operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.
A financial analysis of Gilead Sciences is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of Gilead Sciences completes this in-depth company analysis.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...
The global antiviral drugs market is expected to reach a value of USD 69.2 billion by 2025, based on a new report by Grand View Research, Inc. According to the WHO, cases of viral infections increase by ...
In 2016, the global antiviral market was estimated to be worth USD 30.84 billion and is expected to reach revenues of approximately USD 40.71 billion by 2022 at a CAGR of 5.71% between 2016 and 2022. The ...